Professor, Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Speciality Interests

Chemotherapy and clinical trials in gastrointestinal and genitourinary cancers

Schedule

schedule of week
11 MON
25
TUE
26
WEN
27
THU
28
FRI
29
AM
PM

Medical School

Konkuk University College of Medicine, Seoul, Korea

Specialty Training

Specialty Training
Fellowship   Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Seoul, Korea
Residency   Samsung Medical Center, Seoul, Korea
Internship   Samsung Medical Center, Seoul, Korea

Participation in Academic Societies
and Research

  • A member of the Korean Cancer Association and the Korean Association for Clinical Oncology
    A member of the American Society of Clinical Oncology and the European Society for Medical Oncology

Thesis

J PERS MED 2021 10.3390/jpm11060575

Detection of Aberrant Glycosylation of Serum Haptoglobin for Gastric Cancer Diagnosis Using a Middle-Up-Down Glycoproteome Platform

Jeong1, S; Kim, U; Oh, M; Nam, J; Park, S; Choi, Y; Lee, D; Kim, J; An, H

NEW ENGL J MED 2021 10.1056/NEJMoa2034442

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

Bajorin1, DF; Witjes, JA; Gschwend, JE; Schenker, M; Valderrama, BP; Tomita, Y; Bamias, A; Lebret, T; Shariat, SF; Park, SH; Ye, D; Agerbaek, M; Enting, D; McDermott, R; Gajate, P; Peer, A; Milowsky, MI; Nosov, A; Antonio, JN; Tupikowski, K; Toms, L; Fischer, BS; Qureshi, A; Collette, S; Unsal-Kacmaz, K; Broughton, E; Zardavas, D; Koon, HB; Galsky, MD

LANCET ONCOL 2021 10.1016/S1470-2045(21)00094-2

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial

Yu1, EY; Petrylak, DP; O'Donnell, PH; Lee, JL; van der Heijden, MS; Loriot, Y; Stein, MN; Necchi, A; Kojima, T; Harrison, MR; Park, SH; Quinn, DI; Heath, EI; Rosenberg, JE; Steinberg, J; Liang, SY; Trowbridge, J; Campbell, M; McGregor, B; Balar, AV

KOREAN J INTERN MED 2021 10.3904/kjim.2020.213

2020 Korean guidelines for the management of metastatic prostate cancer

Kim1, IH; Shin, SJ; Kang, BW; Kang, J; Kim, D; Kim, M; Kim, JY; Kim, CK; Kim, HJ; Maeng, CH; Park, K; Park, I; Bae, WK; Sohn, BS; Lee, MY; Lee, JL; Lee, J; Lim, ST; Lim, JH; Chang, H; Jung, JY; Choi, YJ; Kim, YS; Cho, J; Joung, JY; Park, SH; Lee, HJ

ANN ONCOL 2021 10.1016/j.annonc.2020.11.017

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial

Park1, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK

CLOSE

Patients' Rights and Responsibilities

Patients' Rights

1. Right to receive medical care

Patients have the right to receive proper care in a safe setting without discrimination nor should their right to care be violated regardless of their gender, age, religion, social status, nationality, language, race, or physical/mental/financial status. Medical teams shall not refuse to provide care without justifiable reason.

2. Right to be informed and to make an autonomous decision

Patients have the right to obtain full and complete information from their medical team, to ask questions, and to determine their agreement or refusal concerning: diagnosis, treatment (purpose, plans and methods), outcomes of care (including unanticipated outcomes), discharge plan, participation in medical research studies, organ transplantation/donation, etc. Within ethical boundaries, patients may discontinue or refuse treatment, request that the medical team explain and suggest alternative treatments, and reserve the right to make their own decisions.

3. Right to confidentiality

Patients' rights to confidentiality regarding their physical/health status and privacy will not be violated. Patients can expect that all medical records/reports and their personal privacy will be kept confidential unless the patient has given consent or disclosure is permitted by law. To ensure their privacy, patients may be informed that Individuals not directly involved in their care may not be present and that the number of guardians accompanying patients to consultation rooms may be limited.

4. Right to request consultation and mediation

In the event of a medical dispute, patients may request consultation and mediation from an internal or external agency (Korea Consumer Agency, Korea Medical Dispute Mediation and Arbitration Agency).

5. Right to have values and beliefs respected

Patients will not be discriminated against because of their culture, religious values, or beliefs, and their rights will not be violated.

6. Right to receive care in a safe setting

Patients have the right to receive hospital-provided care where the patient’s medical information is protected and patient safety can be assured. In addition, patients have the right to be protected from possible dangers that can occur in a hospital and to have stability of mind and body.

Patients' Responsibilities

1. Responsibility to trust and respect the medical team

Patients must accurately inform the medical team of their health condition and must trust and respect the medical team's treatment plan. Patients may be responsible for consequences that result from not following instructions.

2. Responsibility to not use dishonest methods for medical treatment

Patients must reveal their identity before receiving any medical care and must not use false or dishonest methods, such as seeking medical care under disguised ownership.

3. Responsibility to abide by all hospital regulations

Patients are expected to treat all hospital staff and other patients with courtesy and respect; to abide by all hospital rules; and to earnestly fulfill their financial obligation to the hospital. Also, patients and their family members are expected to participate in all safety regulations.